MedTrace Logo

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

NCT05200364 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2025-09-22

No results posted yet for this study

Summary

Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.

Conditions

Interventions

DRUG

STRO-002

intravenous antibody drug conjugate

DRUG

Bevacizumab

anti-VEGF agent

Sponsors & Collaborators

  • Sutro Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Arturo Molina, MD · Sutro Biopharma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-22
Primary Completion
2025-06-01
Completion
2025-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05200364 on ClinicalTrials.gov